As of June 30, 2007, AMT had cash and cash equivalents of EUR 56.3 million, compared to EUR 14.1 million at December 31, 2006.
Very recently AMT obtained an exclusive license from Digna Biotech to commercialize all gene therapy products resulting from the R&D activities performed at the Center for the Study of Applied Medicine (CIMA) at the University of Navarra, Spain. Employing more than 400 researchers, CIMA is one of the leading gene therapy research centers in Europe.
"AMT had an excellent first half of 2007, culminating in its listing on Euronext Amsterdam on June 20. The proceeds from this successful initial public offering will be used to accelerate our development programs and build up a marketing and sales infrastructure in anticipation of the expected commercial roll-out of our lead product in 2009. We expect to make considerable progress over the next 12 month related to our clinical programs and business development activities, and look forward to update our investors as these materialize," said Ronald Lorijn, CEO of AMT.
Conference call and webcast presentation
AMT will conduct a conference call open to the public today at 10.00 CET, which will also be webcast. Netherlands dial in: +31-(0)800-949- 4517 (toll free); US dial in: +1-866-291-4166 (toll free); UK dial in: +44- 207-107-0611. The webcast can be accessed on the investors portion of AMT's website at http://www.amtpharma.com. Please go to the website 15 minutes prior to the call to register, download and install the necessary audio software. Playback of the call will be availably for 24 hours after the call. Dial in: +41-91-612-4330; +44-20-7108-6233; or +1-866-416-2558. The archived webcast also will be available for replay shortly after the close of the call.
|SOURCE Amsterdam Molecular Therapeutics B.V|
Copyright©2007 PR Newswire.
All rights reserved